Acotec Scientific Holdings's Days Sales Outstanding for the
six
months ended in Dec. 2023 was 102.86.
Acotec Scientific Holdings's Days Inventory for the
six
months ended in Dec. 2023 was 539.18.
Acotec Scientific Holdings's Days Payable for the
six
months ended in Dec. 2023 was 74.
Therefore, Acotec Scientific Holdings's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2023 was 568.04.
Acotec Scientific Holdings Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Acotec Scientific Holdings's Cash Conversion Cycle
For the Medical Devices subindustry, Acotec Scientific Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acotec Scientific Holdings's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acotec Scientific Holdings's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Acotec Scientific Holdings's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Acotec Scientific Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Acotec Scientific Holdings Cash Conversion Cycle Related Terms
Thank you for viewing the detailed overview of Acotec Scientific Holdings's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.
Acotec Scientific Holdings (HKSE:06669) Business Description
Acotec Scientific Holdings Ltd is a medical device company. The company is focused on providing leave nothing behind treatment solutions for vascular diseases. It has developed a suite of interventional medical devices featuring world- leading technologies, notably in the fields of drug-coated balloons and thrombus aspiration catheters. The company's commercialized product is Semi-compliant PTCA Balloon (YAN) is a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. Geographically, the company operates from Mainland China, Europe and Other countries and regions. Majority of revenue is generated from Mainland China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06669 has been successfully added to your 